Omada Health, Inc.

EDGAR

Market value

$913.2M

62,037,725 shares as of 2026-11-03, at $14.72 a share (OMDA, IEX close on 2026-11-12) Primary-source evidence

Annual consolidated revenue for 2025: about USD 260.2M, using the latest reported figures. The previous period, 2024, was about USD 169.8M.

Watchlist

Holdings and insider activity

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.

Window: transactions dated on or after 2025-11-17.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
78 transactions, 769,925 shares
Sum of shares × price per share: 14,556,708.8329

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

  • 2026-11-04 Duffy Sean P. M 12,944 5.82
  • 2026-11-04 Duffy Sean P. S 12,944 19.2159
  • 2026-11-04 Duffy Sean P. M 12,944 0
  • 2026-10-05 ROOT JONATHAN D A 694 0
  • 2026-10-05 HILLEMAN JERYL L A 1,214 0

5% holders (Schedule 13D and 13G)

  • Morgan Stanley 5.3% SCHEDULE 13G 09/30/2026
  • FMR LLC 4.6% SCHEDULE 13G/A 09/30/2026
  • Abigail P. Johnson 4.6% SCHEDULE 13G/A 09/30/2026

See all insider transactions

Latest quarter

Revenue

91.3 million USD

2026 Q3 · USD

Exact inputs and evidence

Operating margin

5.28%

2026 Q3 · %

Exact inputs and evidence
  • Operating Income: 4820000 USD Source
  • Revenue: 91306000 USD Source

Operating cash flow

15.1 million USD

2026 Q3 · USD

Exact inputs and evidence
  • Operating Cash Flow: 7313000 USD Source
  • Operating Cash Flow: -7827000 USD Source

Free cash flow

15 million USD

2026 Q3 · USD

Exact inputs and evidence
  • Operating Cash Flow: 7313000 USD Source
  • Operating Cash Flow: -7827000 USD Source
  • Capital Expenditure: 342000 USD Source
  • Capital Expenditure: 224000 USD Source
Cash and cash equivalents
243 million USD Source
Exact value

243151000 USD

Long-term debt including current maturities
0 USD
Exact inputs and evidence

0 USD

  • Long-term debt including current maturities: 0 USD Source
Shares outstanding
62 million shares Source
Exact value

61996000 shares

Reported share-count change

7.10% · 4.11 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence
  • 57887000 shares · 2025-09-30· Source
  • 61996000 shares · 2026-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

333 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Revenue: 260210000 USD · 2025-01-01 – 2025-12-31 Source
  • Revenue: 184364000 USD · 2025-01-01 – 2025-09-30 Source
  • Revenue: 78048000 USD · 2026-01-01 – 2026-03-31 Source
  • Revenue: 87835000 USD · 2026-04-01 – 2026-06-30 Source
  • Revenue: 91306000 USD · 2026-07-01 – 2026-09-30 Source

Net income

14 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Net income: -12778000 USD · 2025-01-01 – 2025-12-31 Source
  • Net income: -17937000 USD · 2025-01-01 – 2025-09-30 Source
  • Net income: -2970000 USD · 2026-01-01 – 2026-03-31 Source
  • Net income: 5294000 USD · 2026-04-01 – 2026-06-30 Source
  • Net income: 6551000 USD · 2026-07-01 – 2026-09-30 Source

Operating cash flow

28.7 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Operating cash flow: 18252000 USD · 2025-01-01 – 2025-12-31 Source
  • Operating cash flow: -3127000 USD · 2025-01-01 – 2025-09-30 Source
  • Operating cash flow: -11834000 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: -7827000 USD · 2026-01-01 – 2026-06-30 Source
  • Operating cash flow: -11834000 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: 7313000 USD · 2026-01-01 – 2026-09-30 Source
  • Operating cash flow: -7827000 USD · 2026-01-01 – 2026-06-30 Source

Capital expenditure

541 thousand USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Capital expenditure: 1322000 USD · 2025-01-01 – 2025-12-31 Source
  • Capital expenditure: 1123000 USD · 2025-01-01 – 2025-09-30 Source
  • Capital expenditure: 78000 USD · 2026-01-01 – 2026-03-31 Source
  • Capital expenditure: 224000 USD · 2026-01-01 – 2026-06-30 Source
  • Capital expenditure: 78000 USD · 2026-01-01 – 2026-03-31 Source
  • Capital expenditure: 342000 USD · 2026-01-01 – 2026-09-30 Source
  • Capital expenditure: 224000 USD · 2026-01-01 – 2026-06-30 Source

Free cash flow

28.2 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Operating cash flow: 18252000 USD · 2025-01-01 – 2025-12-31 Source
  • Operating cash flow: -3127000 USD · 2025-01-01 – 2025-09-30 Source
  • Operating cash flow: -11834000 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: -7827000 USD · 2026-01-01 – 2026-06-30 Source
  • Operating cash flow: -11834000 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: 7313000 USD · 2026-01-01 – 2026-09-30 Source
  • Operating cash flow: -7827000 USD · 2026-01-01 – 2026-06-30 Source
  • Capital expenditure: 1322000 USD · 2025-01-01 – 2025-12-31 Source
  • Capital expenditure: 1123000 USD · 2025-01-01 – 2025-09-30 Source
  • Capital expenditure: 78000 USD · 2026-01-01 – 2026-03-31 Source
  • Capital expenditure: 224000 USD · 2026-01-01 – 2026-06-30 Source
  • Capital expenditure: 78000 USD · 2026-01-01 – 2026-03-31 Source
  • Capital expenditure: 342000 USD · 2026-01-01 – 2026-09-30 Source
  • Capital expenditure: 224000 USD · 2026-01-01 – 2026-06-30 Source

Company performance

Up to ten complete financial years · consolidated figures

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-11-06.

Financial data available through: 2025-12-31.

Coverage by financial measure
  • Revenue: 3 of 11 periods available· newest 2025-12-31
  • Operating income: 3 of 11 periods available· newest 2025-12-31
  • Net income: 3 of 11 periods available· newest 2025-12-31
  • Operating cash flow: 3 of 11 periods available· newest 2025-12-31
  • Capital expenditure: 3 of 11 periods available· newest 2025-12-31
  • Total assets: 2 of 11 periods available· newest 2025-12-31
  • Total liabilities: 2 of 11 periods available· newest 2025-12-31
  • Current assets: 2 of 11 periods available· newest 2025-12-31
  • Current liabilities: 2 of 11 periods available· newest 2025-12-31
  • Cash and cash equivalents: 2 of 11 periods available· newest 2025-12-31
  • Long-term debt including current maturities: 2 of 11 periods available· newest 2025-12-31
  • Shares outstanding: 2 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Revenue

    +53.2%

    Prior period

    USD 169.8 million

    –

    Current period

    USD 260.21 million

    –

    Exact inputs and evidence

    260210000 − 169800000 = 90410000 USD

    169800000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    260210000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Net income

    +USD 34.36 million

    Prior period

    −USD 47.14 million

    –

    Current period

    −USD 12.78 million

    –

    Exact inputs and evidence

    -12778000 − -47137000 = 34359000 USD

    -47137000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -12778000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    +USD 52.43 million

    Prior period

    −USD 34.18 million

    –

    Current period

    USD 18.25 million

    –

    Exact inputs and evidence

    18252000 − -34179000 = 52431000 USD

    -34179000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    18252000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Capital expenditure

    +121.8%

    Prior period

    USD 596,000

    –

    Current period

    USD 1.32 million

    –

    Exact inputs and evidence

    1322000 − 596000 = 726000 USD

    596000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    1322000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

  • Revenue USD 260.21 million 100% of revenue
  • Cost of revenue USD 89.27 million 34% of revenue
  • Operating expenses USD 182.91 million 70% of revenue
  • Operating income −USD 11.97 million −4.6% of revenue
  • Tax, interest and other Derived USD 806,000 0.3% of revenue
  • Net income −USD 12.78 million −4.9% of revenue

Cash

  • Operating cash flow USD 18.25 million 7% of revenue
  • Capital expenditure USD 1.32 million 0.5% of revenue
  • Free cash flow Derived USD 16.93 million 6.5% of revenue

Share of revenue by period

  • Net income
  • Tax, interest and other
  • Operating costs
  • 2023 Operating loss: operating costs were 154% of revenue.
  • 2024 Operating loss: operating costs were 126% of revenue.
  • 2025 Operating loss: operating costs were 105% of revenue.
Values and sources
Revenue breakdown by annual reporting period
PeriodRevenueOperating costsOperating incomeTax, interest and otherNet incomeFree cash flowSource
2023 2023-01-01 – 2023-12-31122784000 188781000 Derived -65997000 1514000 Derived -67511000 -50154000 Derived
Source
2024 2024-01-01 – 2024-12-31169800000 213454000 Derived -43654000 3483000 Derived -47137000 -34775000 Derived
Source
2025 2025-01-01 – 2025-12-31260210000 272182000 Derived -11972000 806000 Derived -12778000 16930000 Derived
Source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 260.2M 2025
Revenue historyRevenue reported for each complete financial period. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.281.0M210.8M140.5M70.3M0.0202320242025
Values and sources
Revenue values and source evidence
PeriodSeriesValue(USD)Source evidence
2023Revenue122784000
2024Revenue169800000
2025Revenue260210000

Revenue growth

Change in revenue from the same financial period one year earlier.

53.2% 2025
Revenue growth historyChange in revenue from the same financial period one year earlier. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.58%43%29%14%0%202320242025
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence
2023Year over yearNo prior comparable period
2024Year over year38.3%
2025Year over year53.2%

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -4.6% 2025
Net margin -4.9% 2025
Free cash flow margin 6.5% 2025
Profit margins historyOperating income, net income and free cash flow as a share of revenue. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.11%-6%-24%-42%-60%202320242025
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence
2023Operating margin-53.8%
2024Operating margin-25.7%
2025Operating margin-4.6%
2023Net margin-55%
2024Net margin-27.8%
2025Net margin-4.9%
2023Free cash flow margin-40.8%
2024Free cash flow margin-20.5%
2025Free cash flow margin6.5%

Operating cash flow

Cash generated by the company’s normal business operations.

USD 18.3M 2025
Operating cash flow historyCash generated by the company’s normal business operations. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.23.7M4.0M-15.7M-35.5M-55.2M202320242025
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence
2023Operating cash flow-49738000
2024Operating cash flow-34179000
2025Operating cash flow18252000

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 16.9M 2025
Free cash flow historyOperating cash flow minus capital expenditure for the same period and unit. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.22.3M2.8M-16.6M-36.1M-55.5M202320242025
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence
2023Free cash flow-50154000
2024Free cash flow-34775000
2025Free cash flow16930000

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

24.8% 2025
Liabilities to assets historyTotal liabilities as a share of total assets. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.62%46%31%15%0%2023-12-3120242025
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence
2023-12-31Liabilities / assetsNot reportedNo source recorded
2024Liabilities / assets57.2%
2025Liabilities / assets24.8%

Current assets to current liabilities

Current assets divided by current liabilities.

3.6× 2025
Current assets to current liabilities historyCurrent assets divided by current liabilities. Values are shown by financial reporting period. Open Values and sources below for the exact observations and evidence.3.89×2.92×1.95×0.97×0.00×2023-12-3120242025
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence
2023-12-31Current assets / current liabilitiesNot reportedNo source recorded
2024Current assets / current liabilities2.1×
2025Current assets / current liabilities3.6×

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2023 2023-01-01 – 2023-12-31
−USD 67.51 million
Exact value

Exact value: -67511000 USD

2023-01-01 – 2023-12-31: -67511000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 49.74 million
Exact value

Exact value: -49738000 USD

2023-01-01 – 2023-12-31: -49738000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 416,000
Exact value

Exact value: 416000 USD

2023-01-01 – 2023-12-31: 416000 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 50.15 million
Calculation and evidence

-49738000 − 416000 USD

Exact free cash flow: -50154000 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2024 2024-01-01 – 2024-12-31
−USD 47.14 million
Exact value

Exact value: -47137000 USD

2024-01-01 – 2024-12-31: -47137000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 34.18 million
Exact value

Exact value: -34179000 USD

2024-01-01 – 2024-12-31: -34179000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 596,000
Exact value

Exact value: 596000 USD

2024-01-01 – 2024-12-31: 596000 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 34.78 million
Calculation and evidence

-34179000 − 596000 USD

Exact free cash flow: -34775000 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2025 2025-01-01 – 2025-12-31
−USD 12.78 million
Exact value

Exact value: -12778000 USD

2025-01-01 – 2025-12-31: -12778000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 18.25 million
Exact value

Exact value: 18252000 USD

2025-01-01 – 2025-12-31: 18252000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 1.32 million
Exact value

Exact value: 1322000 USD

2025-01-01 – 2025-12-31: 1322000 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 16.93 million
Calculation and evidence

18252000 − 1322000 USD

Exact free cash flow: 16930000 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

9 filings · 850 latest values · 850 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001611115, 1611115, OMDA, edgar:1611115

Also known as Omada Health, Inc.